On this page
GATA2 deficiency
This inherited disorder can lead to a range of health problems including infections, certain blood cancers, and lymphoedema. It typically affects individuals from childhood through to adulthood, with varying severity.
Overview
GATA2 deficiency is an inherited disorder caused by changes in the GATA2 gene. This condition primarily impacts the normal development and function of several types of blood cells, including white blood cells that are crucial for the immune system [PMID:21339474]. People with GATA2 deficiency often have weakened immune systems, making them more susceptible to recurrent infections.
The condition can also lead to issues with bone marrow function, which may result in a shortage of different blood cell types. Over time, individuals with GATA2 deficiency have an increased risk of developing certain blood cancers, such as myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) [PMID:21339474]. The severity and specific health problems associated with GATA2 deficiency can vary significantly between affected individuals.
Symptoms & clinical features
The symptoms of GATA2 deficiency are varied and can affect different body systems. Recurrent infections are a common feature, often caused by bacteria, fungi, or viruses, due to a compromised immune system [PMID:23748239]. These infections can sometimes be severe or unusual.
Another frequent symptom is lymphoedema, which is chronic swelling, most commonly in the legs, arms, or genital area, caused by a buildup of lymphatic fluid. Some individuals may experience abnormalities in blood count, such as neutropenia (low neutrophils, a type of white blood cell), monocytopenia (low monocytes, another white blood cell type), or pancytopenia (low counts of all blood cells). Hearing loss can also occur in some people with GATA2 deficiency. The condition can sometimes lead to issues with pulmonary (lung) function, although this is less common.
Video: Genetics 101
Affected organs
GATA2 deficiency primarily affects the bone marrow, where blood cells are produced, and consequently impacts the immune system. The bone marrow's inability to consistently produce healthy blood cells leads to immunodeficiency. Lymphatic vessels, responsible for draining fluid and part of the immune system, can also be affected, leading to lymphoedema. In some cases, the condition may impact other organs such as the ears, causing hearing loss, and potentially the lungs. Kidneys can also be affected, with some individuals experiencing kidney dysfunction.
Risks & severity
The severity of GATA2 deficiency can range from mild symptoms to life-threatening complications. A significant risk for individuals with GATA2 deficiency is the potential progression to myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) [PMID:23748239]. The lifetime risk for developing MDS or AML is estimated to be over 50% for individuals with GATA2 deficiency, though this can vary. These conditions are typically serious and require intensive treatment.
The age of onset for symptoms is also variable, with some individuals presenting in childhood and others not until adulthood. Recurrent infections can lead to significant morbidity, and if left untreated, can become very serious. The risk of specific complications and their severity can depend on the exact genetic change in the GATA2 gene and other individual factors.
Genetic causes
GATA2 deficiency is caused by pathogenic variants in the GATA2 gene. This gene provides instructions for making a protein called GATA2, which is a transcription factor. Transcription factors are proteins that bind to specific DNA sequences and help control the activity of other genes. The GATA2 protein plays a critical role in the growth, development, and function of various types of blood cells, including lymphatic cells, and cells of the immune system [PMID:21339474].
When there are pathogenic changes in the GATA2 gene, the GATA2 protein may be either reduced in amount or may not function correctly. This disruption impairs the normal development of blood cells in the bone marrow, leading to the diverse clinical features seen in GATA2 deficiency, such as immune system problems and an increased risk of certain blood cancers. The exact functional consequence of different GATA2 variants can influence the specific clinical presentation.
- GATA2 GATA binding protein 2
Inheritance pattern
GATA2 deficiency is inherited in an autosomal dominant pattern. This means that a person only needs one copy of the altered GATA2 gene in each cell to develop the condition. In most cases, an affected person inherits the altered gene from one affected parent. However, some cases can occur spontaneously, meaning the genetic change happens for the first time in the affected individual and is not inherited from either parent. Each child of an individual with GATA2 deficiency has a 50% chance of inheriting the altered gene.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of GATA2 deficiency typically begins with clinical suspicion based on a combination of symptoms, such as recurrent infections, unexplained low blood counts, lymphoedema, or a family history of the condition. Initial investigations may include full blood counts and immunological assessments to check immune cell levels and function.
Confirmation of GATA2 deficiency is made through genetic testing, which looks for pathogenic variants in the GATA2 gene. Referrals for genetic testing in the UK are often made through a clinical genetics service or a specialist haematology/immunology team. This testing falls under the NHS Genomic Medicine Service (GMS) pathways, with relevant R-codes for immune disorders or bone marrow failure conditions. Genetic counselling is an integral part of the diagnostic process, offering support and information to individuals and families.
Management & lifestyle
Due to the broad spectrum of manifestations, management of GATA2 deficiency is complex and multidisciplinary, focused on monitoring, preventing complications, and treating symptoms. Regular monitoring of blood counts and immune function is crucial, often guided by a haematologist and immunologist. Antibiotics and antifungals may be used to prevent or treat infections.
For individuals with severe bone marrow failure or progressing towards MDS/AML, a bone marrow transplant (also known as a haematopoietic stem cell transplant) may be considered [PMID:23748239]. Lymphoedema management typically involves physiotherapy and compression therapy. Management plans are individualised and developed in collaboration with a specialist NHS team, including clinical geneticists and genetic counsellors, to provide comprehensive, integrated care.
UK care pathway
In the UK, individuals suspected of having GATA2 deficiency would typically be referred to an NHS Genomic Medicine Centre. Diagnosis is usually confirmed through genetic testing, accessible via the NHS Genomic Medicine Service (GMS) pathways, using appropriate R-codes for immunodeficiency or bone marrow failure conditions. Clinical geneticists and genetic counsellors are key points of contact, providing expert advice, coordinating care, and offering family support. Referral to specialist haematology and immunology services within the NHS is also common for ongoing management.
Frequently asked questions
What is lymphoedema and how is it related to GATA2 deficiency?
Lymphoedema is chronic swelling caused by a problem with the lymphatic system, which is part of the immune system. In GATA2 deficiency, changes in the GATA2 gene can affect the development of lymphatic vessels, leading to fluid buildup and swelling, most commonly in the limbs.
Are there different types of GATA2 deficiency?
While it is always caused by a variant in the GATA2 gene, the specific symptoms and their severity can vary a lot between individuals. This variability may be influenced by the exact genetic change and other factors, but it's considered to be one condition.
What is the risk of my children inheriting GATA2 deficiency?
GATA2 deficiency is inherited in an autosomal dominant pattern. If you have the condition, each of your children has a 50% chance of inheriting the altered GATA2 gene. Genetic counselling can provide more specific risk assessments and support.
Can GATA2 deficiency be cured?
There isn't a cure for GATA2 deficiency itself at present, but treatments focus on managing symptoms and preventing complications. For individuals with severe blood cell problems, a bone marrow transplant can be a treatment option that may significantly improve outcomes.
How often do I need to be monitored if I have GATA2 deficiency?
Regular monitoring is essential and usually involves frequent blood tests and check-ups with specialists like haematologists and immunologists. The frequency of monitoring is tailored to each individual's specific health needs and the severity of their condition, as determined by their NHS care team.
References
- Calvo KR, Hickstein DD. The spectrum of GATA2 deficiency syndrome. Blood. 2023. PMID: 36455197
- Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Current opinion in allergy and clinical immunology. 2015. PMID: 25397911
- Liu YC, Eldomery MK, Maciaszek JL. Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications. Annual review of pathology. 2025. PMID: 39357070
- Kotmayer L, Kennedy AL, Wlodarski MW. Germline and somatic genetic landscape of pediatric myelodysplastic syndromes. Haematologica. 2025. PMID: 40568716
- Kotmayer L, Kozyra EJ, Kang G. Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency. Blood cancer journal. 2025. PMID: 40664679
- Fabozzi F, Strocchio L, Mastronuzzi A. GATA2 and marrow failure. Best practice & research. Clinical haematology. 2021. PMID: 34404529
- Kotmayer L, Romero-Moya D, Marin-Bejar O. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. British journal of haematology. 2022. PMID: 35753998
- Molteni E, Bono E, Gallì A. Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity. Blood. 2023. PMID: 37216690